Improving T cell responses to modified peptides in tumor vaccines
- PMID: 22936035
- PMCID: PMC3952016
- DOI: 10.1007/s12026-012-8348-9
Improving T cell responses to modified peptides in tumor vaccines
Abstract
Immune recognition and elimination of cancerous cells is the primary goal of cancer immunotherapy. However, obstacles including immune tolerance and tumor-induced immunosuppression often limit beneficial immune responses. Vaccination is one proposed intervention that may help to overcome these issues and is an active area of study in cancer immunotherapy. Immunizing with tumor antigenic peptides is a promising, straight-forward vaccine strategy hypothesized to boost preexisting antitumor immunity. However, tumor antigens are often weak T cell agonists, attributable to several mechanisms, including immune self-tolerance and poor immunogenicity of self-derived tumor peptides. One strategy for overcoming these mechanisms is vaccination with mimotopes, or peptide mimics of tumor antigens, which alter the antigen presentation and/or T cell activation to increase the expansion of tumor-specific T cells. Evaluation of mimotope vaccine strategies has revealed that even subtle alterations in peptide sequence can dramatically alter antigen presentation and T cell receptor recognition. Most of this research has been performed using T cell clones, which may not be accurate representations of the naturally occurring antitumor response. The relationship between clones generated after mimotope vaccination and the polyclonal T cell repertoire is unclear. Our work with mimotopes in a mouse model of colon carcinoma has revealed important insights into these issues. We propose that the identification of mimotopes based on stimulation of the naturally responding T cell repertoire will dramatically improve the efficacy of mimotope vaccination.
Figures
Similar articles
-
Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.Cancer Res. 2013 Jan 1;73(1):74-85. doi: 10.1158/0008-5472.CAN-12-1005. Epub 2012 Nov 16. Cancer Res. 2013. PMID: 23161490 Free PMC article.
-
Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.Cancer Immunol Res. 2017 Jan;5(1):72-83. doi: 10.1158/2326-6066.CIR-16-0194. Epub 2016 Dec 9. Cancer Immunol Res. 2017. PMID: 27941004 Free PMC article.
-
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.J Biol Chem. 2013 Nov 15;288(46):33213-25. doi: 10.1074/jbc.M113.509554. Epub 2013 Oct 8. J Biol Chem. 2013. PMID: 24106273 Free PMC article.
-
Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.BioDrugs. 2015 Feb;29(1):15-30. doi: 10.1007/s40259-014-0114-1. BioDrugs. 2015. PMID: 25523015 Review.
-
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.Theranostics. 2020 May 15;10(13):6011-6023. doi: 10.7150/thno.38742. eCollection 2020. Theranostics. 2020. PMID: 32483434 Free PMC article. Review.
Cited by
-
Natural heteroclitic-like peptides are generated by SARS-CoV-2 mutations.iScience. 2023 Jun 16;26(6):106940. doi: 10.1016/j.isci.2023.106940. Epub 2023 May 21. iScience. 2023. PMID: 37275517 Free PMC article.
-
Attentive Variational Information Bottleneck for TCR-peptide interaction prediction.Bioinformatics. 2023 Jan 1;39(1):btac820. doi: 10.1093/bioinformatics/btac820. Bioinformatics. 2023. PMID: 36571499 Free PMC article.
-
Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects.Vaccines (Basel). 2022 Nov 25;10(12):2011. doi: 10.3390/vaccines10122011. Vaccines (Basel). 2022. PMID: 36560420 Free PMC article. Review.
-
Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine Melanoma.Front Immunol. 2022 Jun 23;13:886683. doi: 10.3389/fimmu.2022.886683. eCollection 2022. Front Immunol. 2022. PMID: 35812387 Free PMC article.
-
Development of Peptide-Based Vaccines for Cancer.J Oncol. 2022 Mar 15;2022:9749363. doi: 10.1155/2022/9749363. eCollection 2022. J Oncol. 2022. PMID: 35342400 Free PMC article. Review.
References
-
- Thomas L. In Cellular and humoral aspects of the hypersensitive states. In: Lawrence eH., editor. Discussion. New York: Hoeber-Harper; 1959.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
